Physician profile
Amy E Golob
NPI 1114358421
$2,350.99
in general payments reported to CMS, 2019-2025
18 companies · $846 in 2025
The $846 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.72 · 2022: $380 · 2023: $534 · 2024: $498 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $698.43 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Impulse Dynamics (USA) INC. | $339.59 | 2023-2025 | Optimizer, Optimizer |
| Boston Scientific Corporation | $244.71 | 2024-2025 | Farapulse, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $238.89 | 2021-2025 | Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $154.38 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Bridgebio Pharma, INC. | $121.36 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $119.39 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $87.82 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $77.51 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $63.17 | 2023-2025 | |
| Abiomed | $39.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $39.13 | 2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.27 | 2021-2025 | Lifevest |
| Tactile Systems Technology INC | $24.27 | 2025 | Flexitouch Plus, Nimbl |
| American Regent | $23.61 | 2025 | Injectafer |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $20.83 | 2024 | Barostim Neo System |
| Pfizer INC. | $18.40 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Golob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.